Prophylactic treatment of age-related macular degeneration report number 2: 810-Nanometer laser to eyes with drusen: Bilaterally eligible patients

Thomas R. Friberg, Peter M. Brennen, William R. Freeman, David C. Musch, Laurence W. Arend, Barbara Noguchi, Janet Ferran, Denie Cochran, Patricia Corbin, Charles Garcia, Rebecca Gutierrez, R. Joseph Olk, Karen Pollock, Jeffrey D. Benner, Joseph C. Schwartz, Hannah Scott, Keye Wong, Rosa Miller, Carl C. Awh, Kristie McHenryShonta Brown, Mark Short, Lisa Polk, Julia Whitely, Sarah Hines, Amanda Tanton, Nichole McDonald, Howard Lazarus, Paige Bunch, Jennifer I. Lim, Lawrence Chong, Christina J. Flaxel, Ken Diddie, Margaret Padillo, Frances Walonker, Richard B. Rosen, Ronald C. Gentile, Amy Gedal, Lawrence S. Morse, Navid Khodadadi, Daniel Redline, Mark Thomas, Marianna Eckert, David Hauser, Ron Morales, Gregory M. Fox, Donna M. Moyer, Brian B. Berger, Jeni Rathman, Hugo Quiroz-Mercado, Sergio Hernandez Da Mota, Jose Luis Guerrero-Naranjo, Bruce R. Saran, Avice Bourne, Charles H. Barnes, Melanie Frees, Ronald M. Kingsley, Reagan Bradford, Russ Burris, Rob Richmond, Jason Jobson, Connie Dwiggins, Stephen H. Sinclair, Nancy L. Roccio, David Tom, Abby Fiocco, Robert C. Ramsay, Jill B. Johnson, Julianne Enloe, William B. Phillips, Lawrence I. Rand, Cheryl Wallace, John Whitney

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


■ BACKGROUND AND OBJECTIVE: To determine the prophylactic and therapeutic value of a single subthreshold 810-nanometer laser treatment in patients with high risk drusen as a manifestation of dry age-related macular degeneration in both eyes. ■ PATIENTS AND METHODS: The Prophylactic Treatment of Age-related Macular Degeneration study enrolled 1,278 eyes of 639 participants who were 50 years or older with at least 5 drusen 63 μm or more in diameter in each eye. Treatment consisted of the placement of an annular grid of 48 extrafoveal, subthreshold 810-nm diode laser applications centered at but sparing the foveola in one eye of each participant, with the fellow eye serving as a control. Development of choroidal neovascularization and change in best-corrected visual acuity were compared between treated and untreated eyes. ■ RESULTS: Subthreshold laser treatment did not decrease the incidence of choroidal neovascularization in treated versus untreated eyes. A modest visual acuity benefit in treated eyes was found at 24 months (1.5 letter difference; P = .04) and in the treated eyes of participants with a baseline visual acuity between 20/32 and 20/63 (4.0 letter difference; P = .0034). However, this treatment effect was not sustained at 3 years. ■ CONCLUSION: A single subthreshold 810-nanometer laser treatment to eyes of participants with bilateral high risk drusen is not an effective prophylactic strategy against choroidal neovascularization.

Original languageEnglish (US)
Pages (from-to)530-538
Number of pages9
JournalOphthalmic Surgery Lasers and Imaging
Issue number6
StatePublished - Nov 2009
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology


Dive into the research topics of 'Prophylactic treatment of age-related macular degeneration report number 2: 810-Nanometer laser to eyes with drusen: Bilaterally eligible patients'. Together they form a unique fingerprint.

Cite this